Literature DB >> 29859919

Would pan-tuberculosis treatment regimens be cost-effective?

Emily A Kendall1, Grania Brigden2, Christian Lienhardt3, David W Dowdy4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29859919      PMCID： PMC6191652          DOI： 10.1016/S2213-2600(18)30197-8

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  6 in total

Review 1.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Gary Maartens; Kelly E Dooley; Ruth McNerney; Megan Murray; Jennifer Furin; Edward A Nardell; Leslie London; Erica Lessem; Grant Theron; Paul van Helden; Stefan Niemann; Matthias Merker; David Dowdy; Annelies Van Rie; Gilman K H Siu; Jotam G Pasipanodya; Camilla Rodrigues; Taane G Clark; Frik A Sirgel; Aliasgar Esmail; Hsien-Ho Lin; Sachin R Atre; H Simon Schaaf; Kwok Chiu Chang; Christoph Lange; Payam Nahid; Zarir F Udwadia; C Robert Horsburgh; Gavin J Churchyard; Dick Menzies; Anneke C Hesseling; Eric Nuermberger; Helen McIlleron; Kevin P Fennelly; Eric Goemaere; Ernesto Jaramillo; Marcus Low; Carolina Morán Jara; Nesri Padayatchi; Robin M Warren
Journal:  Lancet Respir Med       Date:  2017-03-15       Impact factor: 30.700

2.  WHO recommendations on shorter treatment of multidrug-resistant tuberculosis.

Authors:  Giovanni Sotgiu; Simon Tiberi; Lia D'Ambrosio; Rosella Centis; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet       Date:  2016-06-18       Impact factor: 79.321

3.  Pan-tuberculosis regimens: an argument for.

Authors:  Robert S Wallis; Ted Cohen; Nicolas A Menzies; Gavin Churchyard
Journal:  Lancet Respir Med       Date:  2018-04       Impact factor: 30.700

4.  Pan-tuberculosis regimens: an argument against.

Authors:  Keertan Dheda; Tawanda Gumbo; Christoph Lange; C Robert Horsburgh; Jennifer Furin
Journal:  Lancet Respir Med       Date:  2018-04       Impact factor: 30.700

5.  The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.

Authors:  Gwenan M Knight; Gabriela B Gomez; Peter J Dodd; David Dowdy; Alice Zwerling; William A Wells; Frank Cobelens; Anna Vassall; Richard G White
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

6.  Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Authors:  Emily A Kendall; Sourya Shrestha; Ted Cohen; Eric Nuermberger; Kelly E Dooley; Lice Gonzalez-Angulo; Gavin J Churchyard; Payam Nahid; Michael L Rich; Cathy Bansbach; Thomas Forissier; Christian Lienhardt; David W Dowdy
Journal:  PLoS Med       Date:  2017-01-03       Impact factor: 11.069
  6 in total
  3 in total

1.  Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis.

Authors:  David W Dowdy; Alice A Zwerling; Andrea Stennett; Alexandra Searle; Vadim Dukhanin; Holly A Taylor; Maria W Merritt
Journal:  MDM Policy Pract       Date:  2020-04-26

2.  Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.

Authors:  Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; Claudia M Denkinger; David W Dowdy
Journal:  BMC Infect Dis       Date:  2019-09-09       Impact factor: 3.090

3.  The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.

Authors:  Nimalan Arinaminpathy; Gabriela B Gomez; Kuldeep S Sachdeva; Raghuram Rao; Malik Parmar; Sreenivas A Nair; Kiran Rade; Sameer Kumta; David Hermann; Christy Hanson; Daniel P Chin; Puneet Dewan
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.